← All trials
NCT04453813
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 3, 2020
- Primary completion
- Jul 31, 2025
- Completion date
- Jul 31, 2027
- First posted
- Jul 1, 2020
- Last posted
- Sep 28, 2020
- Enrollment
- 226
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Xiamen UniversityCollaborator
- Sun Yat-Sen UniversityReponsible party - principal investigator
- Sun Yat-Sen UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Wuzhou Red Cross HospitalCollaborator
- Yuebei People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.